Jonathan Zager is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 505 publications with 14,405 citations (h-index 58); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Surgical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-4673Registry record last updated 16 Jan 2008.
Clinical trials
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Sponsor: Delcath Systems Inc.
- Biomarker Correlates of Hypoxia in Metastatic Melanoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Delcath SystemsProgram year20257 payments
- Merit Medical Systems IncProgram year20251 payment
- Immunocore LimitedProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
Journal of the American College of Surgeons
2019 - Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
Expert Opinion on Drug Safety
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”